Parallel-Group Study to Assess the Effect of Rasagiline on Cognition in Patients With Parkinson's Disease

Summary

This is a 24-week, multicenter, randomized, double-blind, placebo-controlled, add-on, parallel-group study to evaluate the effect of rasagiline on cognitive function in adults with mild cognitive impairment (MCI) in Parkinson's disease (PD-MCI).

Timeline

Start

2012-11

Primary completion

2015-01

Completion

2015-01

Outcome

Missed primary endpoint

registry analysis (unspecified test); Rasagiline 1.0 mg/Day vs Placebo; p = 0.2204; Least Squares Mean Difference 0.8 (95% CI -0.48 to 2.05); repeated measures model NCT01723228 ↗

Publications

• Background Hanagasi HA, Gurvit H, Unsalan P, Horozoglu H, Tuncer N, Feyzioglu A, Gunal DI, Yener GG, Cakmur R, Sahin HA, Emre M. The effects of rasagiline on cognitive deficits in Parkinson's disease patients without dementia: a randomized, double-blind, placebo-controlled, multicenter study. Mov Disord. 2011 Aug 15;26(10):1851-8. doi: 10.1002/mds.23738. Epub 2011 Apr 15.

Drugs

Indications